CHD and is associated with increased risk of death and cardiovascular events. 5, 6 Few studies have examined therapeutics that effectively modify MSIMI, [7] [8] [9] perhaps because of the mechanistic complexity underlying this phenomenon, which encompasses a wide range of central and peripheral physiological changes associated with emotions and behaviors. However, recent evidence suggests that selective serotonin reuptake inhibitors (SSRIs) may reduce mental stress-induced hemodynamic response, metabolic risk factors, 10, 11 and platelet activity. 12, 13 We therefore conducted the REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) trial to investigate whether SSRI treatment can improve MSIMI.
METHODS
The REMIT trial was a randomized, double-blind trial comparing the SSRI escitalopram vs placebo in participants with clinically stable CHD and MSIMI. The study was conducted at the Duke University Health System in the United States. The study protocol was reviewed and approved by the Duke institutional review board, and all participants provided written informed consent.
Eligibility and Recruitment
A complete description of the trial methodology has been published. 14 Briefly, we screened all patients with CHD who visited Duke cardiology clinics. Patients 21 years or older were eligible to participate if they had CHD, as documented by angiographic findings of coronary artery stenosis of 70% or greater, history of myocardial infarction, or history of cardiac revascularization. Exclusion criteria included significant cognitive impairment, lifethreatening comorbid conditions (estimated 50% mortality within 1 year), active suicidal ideation, and psychiatric conditions precluding use of SSRIs. 14 Patients who exhibited MSIMI during baseline screening were qualified for the trial intervention.
Race and ethnicity of the REMIT participants was obtained via self-report using the following investigatordefined categories: Hispanic ethnicity: yes or no; race: white, black, Native American, Asian or Pacific Islander, other (specify).
Overall Design
The REMIT trial tested the hypothesis that the SSRI escitalopram would reduce MSIMI to a greater extent than placebo in patients with clinically stable CHD and MSIMI at enrollment. Participants underwent mental and exercise stress testing during baseline screening. Participants who demonstrated MSIMI were randomly allocated in a 1:1 ratio, divided in blocks of 10, in double-blind fashion to receive escitalopram or matching placebo for 6 weeks. Randomization was conducted by the Duke University Medical Center Investigational Drug Service. All randomization information was secured and accessible only to authorized individuals working within the service.
The initial dose of study drug was 5 mg/d, increasing to 10 mg/d in 1 week and to 20 mg/d at week 3 and for the remainder of the study period. If participants were unable to tolerate higher doses, the dose could be decreased to 5 mg/d. Mental and exercise stress testing were repeated at the end of the 6-week intervention. Adherence to study drug was assessed via weekly inquiries and pill counts on return of medication bottles. Study medication was tapered following end point assessments. Participants who preferred to continue with study medication were provided a prescription for a 1-month supply of escitalopram and required to follow up with their primary cardiologist or primary care physician.
Stress-Induced Myocardial Ischemia
All stress tests were conducted at the Duke Cardiac Diagnostic Unit in the morning, following withholding of ␤-blockers for 24 to 48 hours. 14 Three mental stress tasks-mental arithme-tic, mirror trace, and public speaking with anger recall-delivered in the same sequence throughout the study were used to assess MSIMI; each test was followed by a 6-minute rest.
After mental stress testing, participants underwent a treadmill exercise test using the standard Bruce protocol. Exercise testing was terminated according to American College of Sports Medicine guidelines. Testing was repeated at the 6-week end point visit; an alternative mental arithmetic task was used to prevent habituation. Echocardiography and electrocardiography were used to assess ischemia. Left ventricular ejection fraction (LVEF) was calculated from a 3-to 5-beat loop. Wall motion assessments were determined from systole from 1 cardiac cycle at a frame rate of 30 to 40 frames/s using the 16-segment model recommended by the American Society of Echocardiography. These assessments were blinded to randomization and stress tests.
To minimize variation and temporal drift and to enhance reliability, all echocardiographic images from participants who completed both baseline and end point stress testing were batch read by 2 experienced cardiologists (E.J.V., Z.S.) after participants completed the 6-week end point assessments. 15 Blood pressure, heart rate, and standard 12-lead electrocardiography were measured simultaneously during acquisition of echocardiographic images. MSIMI was defined by presence of 1 or more ischemic markers: compared with rest measurements, any development or worsening of regional wall motion; reduction of LVEF by 8% or more; and/or deviation of ST segment (horizontal or downsloping depression of 1 mm or greater) in 2 or more leads, lasting for 3 or more consecutive beats, during 1 or more of the 3 mental stress tasks. Exerciseinduced myocardial ischemia (ESIMI) was defined as development of the above during exercise testing. Continuing presence or absence of any of 3 ischemic markers was evaluated at the 6-week end point visit for both MSIMI and ESIMI.
Other Study Outcomes
Other study outcomes included biophysiological and psychological measurements obtained at baseline and repeated at 6 weeks. Biophysiological measures included resting platelet serotonin (5HT) receptor transporter (5HTT) level (fmol/mg protein), measures of serotonin uptake into platelets (binding affinity [Kd 100 ], nM), and platelet serotonin density of 5HT uptake sites (maximum 5HT uptake rate [V max , fmol/10 7 platelets per 5 minutes). Measures of resting and mental stress-induced LVEF and hemodynamic responses were obtained, including systolic and diastolic blood pressure, heart rate, ratepressure product, exercise capacity (measured via duration of treadmill exercise test, peak heart rate, attainment of target heart rate), ESIMI, and occurrence of chest pain, chest discomfort, shortness of breath, and other physical discomfort during stress testing. Psychological measures included symptoms of depression via Beck Depression Inventory scale, 16 state and trait anxiety via Spielberger State-Trait Anxiety Inventory scales, 17 hostility via Cook-Medley Hostility (Ho) scale, 18 and social stress via Perceived Stress Scale. 19 Two clusters of emotional response to mental and exercise stress testing were obtained via a visual analog scale of 0 to 100: positive emotions included being calm and in control; and negative emotions included frustration, tension, and sadness. 14
Statistical Analysis
Bivariate analyses by treatment assignment were conducted on demographic and clinical variables. Resting LVEF 20 and sex 21 have epidemiologic and clinical relevance to the primary outcome and were included in the adjusted model. The primary outcome of presence of MSIMI at 6 weeks and its association with treatment assignment was examined under the intention-to-treat (ITT) principle using logistic regression. We used multiple imputation techniques 22 to compensate for potential bias introduced by missing end point data. The imputed model to predict the outcome consisted of age, baseline resting LVEF, sex, and the treatment variable. For our primary outcome, unadjusted and adjusted imputed logistic regression models provided odds ratios (ORs) and 95% CIs for the association of the study intervention with MSIMI. The Hosmer-Lemeshow statistic was reported as a goodnessof-fit index for this model.
For the primary outcome, perprotocol analysis was also conducted among participants who completed baseline and end point assessments. Secondary outcomes were classified into biophysiological and psychological outcomes. A general linear model was used for continuous variables and logistic regression for dichotomized outcomes; these models were controlled for sex and baseline corresponding values. To enhance reliability of mental stress assessments under various domains and reduce the number of statistical tests, we averaged the 3 mental stress measurements. Analysis was also conducted among participants who comp l e t e d b a s e l i n e a n d e n d p o i n t assessments (per-protocol sample) for secondary outcomes. Because the results of the ITT and the per-protocol samples were similar, we chose to present the results of the ITT analyses (FIGURE). All tests performed were 2-sided.
Primary results were examined at a significance level of .05. For secondary outcomes, ␣ was fixed at .05, and Bonferroni adjustment was used for the number of variables in each domain. This resulted in a critical value of P=.05/ 9=.006 for the analysis of the biophysiological outcomes and a critical value of P=.10/7=.007 for the analysis of the psychological outcomes. All analyses were performed using SAS version 9.3 (SAS Institute Inc).
The study was designed to have at least 80% power to detect betweengroup differences on MSIMI improvement or no MSIMI at the end of the 6-week treatment period. For a sample of 60 participants in each treatment group, we estimated to observe 30% improvement in MSIMI in the placebo group and greater than 60% MSIMI improvement in the escitalopram group. With these estimates and a 2-sided ␣ = .05, the study had greater than 80% power with up to 10 dropouts. Because we experienced more dropouts than anticipated, with the approval of the study data and safety monitoring board and the Duke i n s t i t u t i o n a l r e v i e w b o a r d w e increased total enrollment from 120 to 127 to ensure that at least 110 participants completed the baseline and the 6-week assessments.
RESULTS

Participant Characteristics and Baseline Assessments
A total of 127 participants with clinically stable CHD and MSIMI at baseline screening were randomized; 112 (56 in each group) completed end point assessments ( Figure) . Demographic and clinical characteristics and baseline cardiovascular and emotional measures by treatment group are summarized in TABLE 1 and TABLE 2, respectively. Participants allocated to receive escitalopram were significantly older than those assigned to receive placebo (66.5 vs 61.4 years, P=.01). Participants allocated to receive placebo were more likely to be women and had higher rates of resting abnormal wall motion and lower LVEF, although differences between groups were not statistically significant. The majority of participants were taking aspirin, statins, and ␤-blockers; approximately 45% were taking other antiplatelet agents; and nearly 80% were taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (Table 1 ). No differences in medication use by treatment group were noted.
Study Drug Treatment and Discontinuation
Fifteen participants withdrew during the intervention: 8 in the escitalopram group and 7 in the placebo group ( Figure) . Seven (46.7%) withdrew prior to receiving study medication; 6 (40.0%) withdrew during week 1; and 2 (13.3%) dropped out after week 3. Of these 2 late dropouts, 1 was attributable to the primary cardiologist's request for cardiac catheterization; the other was attributable to death at week 5. Most study participants took the maximum dose of the study drug (54 [87.1%] in the escitalopram group; 57 [93.4%] in the placebo group) (TABLE 3) . Adherence to study medication was defined as taking at least 75% of study medication and was assessed by pill counts at study visits. Overall, 107 of 112 study participants completing end point assessment were considered adherent to study medication (54/56 [96%] in the escitalopram group and 53/56 [95%] in the placebo group).
Primary Outcomes
Of the 127 participants randomized, 64 (50.4%) were allocated to receive escitalopram and 63 (49.6%) to receive placebo. A total of 112 (88.2%; n=56 for both groups) completed end point assessments ( Figure) . Although all 127 participants had either new regional wall motion abnormalities, decrease in LVEF of 8% or more, or both during 1 or more of 3 mental stress tests during baseline assessment, 5 of the 112 participants who completed follow-up were reassessed by reviewers (E.J.V., Z.S.) as having no MSIMI at baseline (TABLE 4) . No patients had any mental stressinduced ischemic ST-segment changes, either at baseline or at 6-week assessments. Of 5 participants whose baseline MSIMI was reclassified as "no MSIMI," 4 had no MSIMI at 6 weeks; 1 participant assigned to receive escitalopram developed MSIMI. Intrarater and interrater variability of wall motion analysis as assessed by the statistic ranged from 0.80 to 0.87, consistent with previous results. 14 At the end of 6 weeks, more patients taking escitalopram ( . Hemodynamic responses to mental stress were all lower in the escitalopram group; differences in heart rate and rate-pressure product between groups were significant. Weight and body mass index (BMI) were also reduced in the escitalopram group compared with placebo, but the reduction was not significant. Participants receiving escitalopram did not exhibit greater alteration in the rate of ESIMI in either unad- Abbreviations: BMI, body mass index; ESIMI, exercise stress-induced myocardial ischemia; KD, platelet serotonin binding affinity; LVEF, left ventricular ejection fraction; MSIMI, mental stress-induced myocardial ischemia; 5HTT, serotonin transporter; VMAX, maximum serotonin uptake rate. a None of these variables were statistically different between the escitalopram and the placebo groups. b Calculated as weight in kilograms divided by height in meters squared. c Score range, 0 to 63 (higher score=greater severity of depressive symptoms). d Score range, 10 to 50 (higher score=greater levels of perceived stress). e Measured using Cook-Medley Hostility (Ho) scale. Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility); hostile affect, 0 to 5 (higher score=greater levels of hostile affect). f Measured using Spielberger State-Trait Anxiety Inventory scales. Score ranges: trait anxiety, 20 to 80 (higher score=greater levels of trait anxiety); state anxiety, 20 to 80 (higher score=greater levels of state anxiety). g Measured by visual analog scale (0-100; higher score=greater levels of state negative or positive affect).
Psychological Outcomes
Scores of symptoms of depression, trait anxiety, and perceived stress improved at 6 weeks in both intervention groups, but no differences between groups were observed (Table 5 ). State anxiety scores im-provedatweek6intheescitalopramgroup and worsened in the placebo group, but the treatment effect was statistically nonsignificantafteradjustingforsexandbaselinestateanxiety(Table5).Hostilityscores remained similar over the 6-week trial across both groups. During end point mental stress testing, participants in the escitalopramgroupfeltsignificantlymore in control and calmer than those in the placebo group. Negative emotional responses to mental stress were less intense in the escitalopram group than in the placebo group, but the group difference was not significant. Participants in the escitalopram group also showed less reductioninpositiveaffectduringmentalstress; the difference remained significant after adjustingforsexandbaselinescore(Ϫ22.6 [95%CI,Ϫ27.4toϪ17.9]vsϪ29.4[95% CI, Ϫ34.2 to Ϫ24.6]; P=.05).
Tolerability and Safety
A significantly higher proportion of participants in the escitalopram group reported adverse effects compared with participants in the placebo group (46 [71.9%] vs 28 [44.4%], P = .002) ( Table 3) . Adverse effects were relatively mild. Two participants withdrew because of adverse effects considered probably attributable to escitalopram (Figure) . 
DISCUSSION
The REMIT randomized, doubleblind, placebo-controlled trial demonstrated that participants with stable CHD receiving escitalopram had an odds of 2.62 of not experiencing MSIMI at week 6, compared with those receiving placebo. Six weeks of escitalopram treatment reduced the number of platelet serotonin receptor transporters and altered the transporter binding affinity density of 5HT uptake sites, compared with the placebo group. Further, the 6-week escitalopram intervention was associated with greater improvements in hemodynamic responses to mental stress and certain measures of psychological functioning, including state anxiety and positive affect, during mental stress. Escitalopram had no effect on exercise-induced ischemia. MSIMI in patients with clinically stable CHD has been abundantly documented. 4, 23 Consistent findings demonstrate that MSIMI, as documented by new wall motion abnor- Abbreviations: BMI, body mass index; ESIMI, exercise stress-induced myocardial ischemia; KD, platelet serotonin binding affinity; LVEF, left ventricular ejection fraction; MSIMI, mental stress-induced myocardial ischemia; 5HTT, serotonin transporter; VMAX, maximum serotonin uptake rate. a Except where noted, all values presented are adjusted end point scores and include 95% CIs. b P values presented here are adjusted value with age, sex, and the corresponding baseline measurement. c Response rates were calculated from 10 imputed data sets: n=225 of 640 for escitalopram and n=111 of 630 for placebo groups, respectively. d Calculated as weight in kilograms divided by height in meters squared. e See Table 2 for score ranges. f Measured by visual analog scale (0-100; higher score=greater levels of state negative or positive affect). mality, LVEF reduction of 5% or more or of 8% or more, and/or ischemic changes on electrocardiography, is common in patients with clinically stable CHD. 5 MSIMI is not well associated with conventional cardiovascular risks 5, 23 but like exercise-induced ischemia does predict future adverse cardiovascular prognosis. 5, 6, 24 Some data suggest that MSIMI may offer additional prognostic ability compared with ESIMI. 6 However, despite the clinical significance of MSIMI, there has been relatively little investigation of pharmacotherapeutic interventions for this condition. Two previous studies each used a crosssectional design to test, respectively, the effects of 4 weeks of metoprolol 7 on mental stress-induced wall motion abnormality in 19 participants and the effects of 4 weeks of nifedipine GITS (Gastrointestinal Therapeutic System) vs atenolol 8 on reduction of mental stress-induced LVEF in 15 patients. Rates of MSIMI prior to study intervention were 74% and 33% in these studies, respectively; because of their small sample sizes, neither study proved definitive. 7, 8 The present study demonstrates that escitalopram use was associated with an odds ratio of 2.62 for absence of MSIMI compared with placebo. The improvement of MSIMI was seen with both mental stress-induced wall motion abnormality and LVEF decrease of 8% or more ( Table 5) .
Randomized trials examining cardiovascular benefits of SSRI therapy have yielded mixed results. For instance, both of the SADHART (Sertraline Antidepressant Heart Attack Randomized Trial) studies showed no benefit for sertaline vs placebo for several cardiovascular measurements 25 and composite scores. 26 However, a secondary analysis of the ENRICHD (Enhancing Recovery in Coronary Heart Disease) trial found that, after myocardial infarction, depressed patients who received SSRIs during the trial had lower rates of mortality than depressed patients not taking an SSRI. 27 Several studies have examined the effects of SSRIs on metabolic risk factors of cardiovascular diseases. A number of investigators have reported that fluoxetine improved insulin sensitivity and glucose tolerance in small samples of patients with type 2 diabetes. [28] [29] [30] [31] [32] [33] Kamarck et al 34 studied the effects of citalopram on metabolic measurements and hostility in 159 healthy individuals who had high levels of hostility at baseline. The authors reported that 2 months of citalopram (40 mg/d) favorably changed metabolic risk factors, including BMI, waist circumference, glucose levels, levels of highdensity lipoprotein cholesterol and triglycerides, insulin sensitivity, and resting diastolic blood pressure (all PϽ.05 vs placebo). Citalopram also resulted in greater reduction of hostile affect; this reduction was a mediator in the improvement of diastolic blood pressure. 11, 34 A study by Golding et al 10 of 4 weeks of paroxetine therapy in 8 healthy individuals resulted in a 10% to 15% reduction in systolic and diastolic blood pressure responses to mental stress relative to measures obtained while participants were receiving placebo.
Except for weight and BMI, our study did not assess metabolic risk factors. Otherwise, our findings accord with those of Kamarck et al 34 and Golding et al. 10 The observed lack of significant reductions in weight and BMI and lack of improvement in hostile affect may reflect the shorter duration of the study and the severity of disease among participants. Nonetheless, our findings support the hypothesis that shortterm use of SSRIs improves levels of biomarkers associated with adverse cardiovascular prognosis.
Psychosocial functioning (eg, depression, anxiety, and hostility) was not a study selection criterion. We deliberately did not specify the potential psychological effects of escitalopram on participants during consent and intervention, because the study primarily aimed at assessing effects on MSIMI. Similar to Kamarck et al, 34 we did not find that escitalopram had a favorable effect on reducing depressive symptoms. Although state anxiety improved among participants receiving escitalopram, especially with regard to emotional reactions to mental stress testing, trait anxiety remained unchanged. This might be attributable to the short-term intervention, might reflect a study population without clinically significant depression and anxiety, or both. However, participants receiving escitalopram reported feeling calmer and more in control during the week 6 mental stress protocol relative to those receiving placebo. This finding is notable because positive expectations and attitudes have been shown to be associated with lower rates of mortality in patients with CHD. 35 Myocardial ischemia reflects an imbalance in a complex process involving increases in the determinants of myocardial oxygen demand as well as decrease of coronary blood supply. 36 Hemodynamic responses to mental stress differ fundamentally from exercise-induced stress, in that mental stress causes little increase in heart rate and a lower-grade increase in systolic blood pressure relative to physical stress. 23 The underlying pathological process of MSIMI is poorly understood. Current models posit that MSIMI is attributable to constriction of small or microcoronary arteries in the context of endothelial dysfunction or atherosclerosis, resulting from dysregulation of the central nervous system and hypothalamicpituitary-adrenal axis system in response to emotional stress. Our study shows that escitalopram can significantly reduce MSIMI that cannot be modified by conventional antiischemic agents and suggests that enhancing central synaptic availability of serotonin may be an important step in management of CHD.
Another potential mechanistic explanation is that SSRIs reduce platelet aggregation. 37 Reduction of platelet aggregation through inhibition of the 5HT receptor by the receptor agonist, even when initiated after onset of recurrent thrombosis, significantly improved coronary patency in a canine model. 38 Escitalopram was seen to significantly alter platelet serotonin receptor transport volume and affinity in our study. Further evaluation of associations of such alterations with changes in platelet aggregation and MSIMI will provide additional mechanistic insight. Whether MSIMI improvement results from changes in cardiovascular reaction to mental stress, psychological modification, or both deserves further exploration.
Limitations
A number of limitations of our study should be noted. Prestratification of baseline demographic and clinical characteristics for equal randomization was not applied because of the relatively small sample size. In addition, based on the multiple-imputation ITT analysis, rates of MSIMI in the treatment group (65.8%) and the placebo group (82.5%) were higher than the original estimate (40% and 70% in treatment and placebo groups, respectively). The study power was thus lower than expected. 14 In addition, although dropout of participants was balanced between treatment groups, the number of dropouts could potentially have had an effect on our findings.
The present study did not address whether reductions in MSIMI at 6 weeks reached the ceiling effect and was not designed to test SSRI effects on major adverse cardiovascular events. In addition, we delivered the 3 mental tasks in the same sequence throughout the study for comparative consistency; thus, individual task potency could not be evaluated. Further, it is possible that an effect on MSIMI caused by 1 task might have been carried forward to affect a subsequent task, although we believe the 6-minute rest period would allow the cardiovascular system to recover from the stress. However, because the primary outcome assessed whether a participant had MSIMI with any of the 3 mental tasks, study findings were not adversely affected by such an arrangement. The REMIT trial was conducted at a single large tertiary-care academic medical center; as such, study find-ings may not be generalizable to different patient populations or care environments. In addition, the limited power leaves uncertainty about the precise magnitude of the effects of treatment. The loss of statistical significance after adjustment for sex and baseline LVEF adds ambiguity to the interpretation of the findings and emphasizes the need for confirmation of these results in other trials before they are considered definitive.
In summary, 6-week pharmacologic enhancement of serotonergic function superimposed on the best evidence-based management of CHD appeared to significantly improve MSIMI occurrence. These results support and extend previous findings suggesting that modifying central and peripheral serotonergic function could improve CHD symptoms and may have implications for understanding the pathways by which negative emotions affect cardiovascular prognosis.
